Neoplasms

All Conditions

Carcinoma

Adenocarcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Agents

All Drugs and Chemicals

Pancrelipase

Pancreatin

Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas

collection of biological samples

Barbara BOURNET, MD, PhD

Cindy CANIVET, PhD

Véronique VENDRELY, MD

Hélène VANDAMME, MD

Guillaume PIESSEN, MD

Stépahnie TRUANT, MD

Bertrand NAPOLEON, MD

Pascal ARTRU, MD

Bertrand PUJOL, MD

Fabien FUMEX, MD

Jérôme DESRAME, MD

Gérard LLEDO, MD

Christine LEFORT, MD

Vincent LEPILLIEZ, MD

Eric ASSENAT, MD

Nicolas FLORI, MD

Philippe BARTHELEMY, Md

Nicolas CARRERE, MD

Fabrice MUSCARI, MD

Rosine GUIMBAUD, MD

Corinne COUTEAU, MD

Marion DESLANDRES, MD

Pascale RIVERA, MD

Marion JAFFRELOT, MD

Nadim FARES, MD

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy).

The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on:

* the development of new diagnostic tools,
* understanding the development of tumors of the pancreas
* the development of new therapeutic targets
* understanding the response to chemotherapy...

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

This collection is coming to enrich the prospective BACAP collection of fresh tumor tissue and/or fixed from the micro-biopsy under endoscopic ultrasound

University Hospital, Toulouse

Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas

Collection of biological samples

Barbara BOURNET, MD; PHD

Cindy CANIVET, PHD

Véronique VENDRELY., MD

Pascal HAMMEL, MD; PHD

Stéphanie TRUANT, MD; PHD

Guillaume PIESSEN, MD; PHD

Pierre GUIBERT, MD

Bertrand NAPOLEON

Jean-François SEITZ, MD; PHD

Stéphane GARCIA

Fréderic BIBEAU, MD; PHD

Eric ASSENAT, MD, PHD

Geoffroy VANBIERVLIET, MD; PHD

Dominique FARGE-BANCEL, MD, PHD

Laurent PALAZZO, MD

Philippe BERTHELEMY, MD

Louis BUSCAIL, MD; PHD

Jean-Yves SCOAZEC, MD; PHD

BACAP is a biobank dedicated to the pancreatic adenocarcinoma funded by institut national institue du cancer (INCa) and coordinated by Dr Barbara Bournet from Toulouse hospital. This base includes clinical data and biological samples such as blood, serum, plasma, saliva, DNA and RNA from tumors cells.

The mission of this prospective project is to make available to the scientific community a clinical biological base from patients with pancreatic adenocarcinoma

Pancreatic cancer represents the fifth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is impossible due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice.

The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy). The present project aims at creating a multicentre national network used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma, built on the best quality standards, for the biological resources as well as the associated clinical and epidemiological data.

The originality of this CBB relies on the fact that it will have not only tumour tissues sampled from surgical specimens of resectable tumours but also cell and biopsy material from unresectable and/or metastatic tumours sampled under endoscopic ultrasonography (1500 biopsies over 3 years coupled to systematic blood samples). Endoscopic ultrasonography is a technique used to specifically perform biopsies on pancreatic tumours and to obtain useful cell material for research. To these samples will be associated every clinical and epidemiological target data required for research projects related to this unique CBB in France. From these samples, DNA and RNA will be especially isolated, as it is a precious biological material for the programmed molecular analyses.

There are many stakes: creating a French network in order to form, with the prospective plans over 3 years, a collection of tissue, biopsies, nucleic acids from pancreatic cancer associated to circulating blood samples and relevant clinical data. Thanks to this collection, the investigator team hope to be able to identify new molecular markers (from cancer tissue and/or circulating blood from pancreatic cancer patients) applicable to clinical practice to diagnose, to assess the prognosis or to predict the response to pancreatic cancer chemotherapy. The investigator team will also try to identify new risk factors for this cancer, especially regarding the diet. The base will thus be made up from 12 different French centres from University Hospital and private Centres where gastroenterologists, oncologists, digestive surgeons, anatomopathologists, epidemiologists intervene as they are all associated to scientific teams dedicated to pancreatic cancer, itself already formed in collaborative networks.

Investigators hope through this project: to get a unique and exceptional CBB for pancreatic cancer, to reach the required standards (especially Inca) for this CBB, and to be internationally recognised. This base will be a strong guarantee to identify new molecular markers for the diagnosis, the prognosis, and the predictive response to chemotherapy for pancreatic cancer, especially when locally advanced. Finally, the epidemiological projects related to this project are originally about the nutritional issues (regardless of the lipid diet and the cachexia) associated to pancreatic cancer.

Whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsie, tissue from tumor and adjacent tissue of pancreas

Biological and Clinical Database for Pancreatic Adenocarcinoma

The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma

Heart and Blood Diseases

Thrombosis

Embolism

Thromboembolism

Embolism and Thrombosis

Venous Thrombosis

Vascular Diseases

All the patients are included in one arm. They will undergo various type of samples.

Françis Couturaud, Pr

Venous thromboembolic disease (VTE) is a common (1/1000), potentially serious disease (10% mortality when the clinical presentation is that of pulmonary embolism (PE)). In cancer patients, the risk of developing VTE is high and constitutes a negative prognostic factor for cancer; the risk of bleeding is also increased. The study of VTE in the context of cancer is a major challenge, given the frequency of the association, the heterogeneity of the situations, the risk factors involved and the therapeutic issues in both curative and primary prevention; in this field, many uncertainties remain, justifying a study focused on the association of VTE and cancer.

Cancer is associated with a higher risk of VTE and mortality. This association is characterized by various uncertainties at pathophysiological, diagnostic, therapeutic and prognostic levels.

CAPE STUDY is a prospective, single-center interventional cohort follow-up study designed to investigate the risk of recurrence of VTE and its mechanisms in cancer patients.

The study involves the collection of biological samples from cancer patients with venous thromboembolic disease.

At inclusion and in case of recurrence of thrombosis or hemorrhage:

* Blood samples will be taken for analysis and to constitute a biobank for future assays.
* Urine samples will be collected Once a year for 5 years (and adapted to the clinical context): visit as part of routine care, or mailing of a questionnaire, or telephone contact.

Blood collected at inclusion (66.4 ml) and in case of recurrence of thrombo-embolic venous disease ( 54.5 mL) to store plasma, serum, DNA and RNA.t Tumor tissue collection (taken during excision or biopsy as part of routine care) Urine (20 to 40 mL)

Cancer-related Venous Thromboembolic Disease - Cohort Study

Establishment of a Patient-based Cohort : Cancer-related Venous Thromboembolic Disease.

All collected data that underlie results in a publication

Fatal haemorrhage, clinical haemorrhage associated with a fall in haemoglobin of 2g/dl or more, clear clinical haemorrhage requiring transfusion of at least 2 red blood cells packed, intracranial, medullary, retroperitoneal, pericardial, intra-articular, intra-muscular, intra-ocular, intra-pulmonary haemorrhage, any other haemorrhage considered serious by the investigator

Global (all causes) and secondary to recurrent VTE or hemorrhage

Atrial fibrillation, cerebrovascular accident, coronary accident, arteriopathy of the lower limbs, digestive vascular accident (splanchnic, renal, mesenteric etc.).

University Hospital, Brest

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Anatomical-Clinical Base of Adenocarcinoma Pancreatic	NCT06128343	Adenocarcinoma Carcinoma Neoplasms	collection of b...	18 Years - 120 Years	University Hospital, Toulouse
Biological and Clinical Database for Pancreatic Adenocarcinoma	NCT02818829	Pancreatic Aden...	Collection of b...	18 Years -	University Hospital, Toulouse
Cancer-related Venous Thromboembolic Disease - Cohort Study	NCT06393764	Thrombosis Embo... Thromboses, Ven... Cancer	Collection of b...	18 Years - 80 Years	University Hospital, Brest
Biological and Clinical Database for Pancreatic Adenocarcinoma	NCT02818829	Pancreatic Aden...	Collection of b...	18 Years -	University Hospital, Toulouse
Cancer-related Venous Thromboembolic Disease - Cohort Study	NCT06393764	Thrombosis Embo... Thromboses, Ven... Cancer	Collection of b...	18 Years - 80 Years	University Hospital, Brest
Anatomical-Clinical Base of Adenocarcinoma Pancreatic	NCT06128343	Adenocarcinoma Carcinoma Neoplasms	collection of b...	18 Years - 120 Years	University Hospital, Toulouse

Spots Global Cancer Trial Database for collection of biological samples